Intracellular Target Engagement Enabled by NanoLuc Luciferase Chemistries

Joel R. Walker², Matt Robers¹, Cesear Corona², Chad Zimprich¹, Mary Hall¹, Jennifer Wilkinson¹, Mei Cong¹, Kassondra Meyer¹, Jim Hartnett¹, Kris Zimmerman¹, Wenhui Zhou²

¹Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711; ²Promega Biosciences LLC, 277 Granada Dr, San Luis Obispo, CA 93401 **Abstract #2127**

1. Introduction

The physical binding of a drug with cellular targets is known as target engagement. Measuring target engagement in a cellular context is an important part of the drug discovery process, as it can address compound cell permeability, equilibrium binding affinity, as well as kinetic binding rates of compound binding and dissociation. However, assessing target engagement in a cellular context has been challenging. We present a biophysical method to directly measure target engagement within intact mammalian cells using bioluminescence energy transfer (BRET).

Four key components are needed:

- Cellular expressed target-NanoLuc fusion
- Cell-permeable fluorescent drug tracer
- Substrate for NanoLuc (Furimazine)
- Extracellular NanoLuc inhibitor

2. Target Engagement using BRET Measurements

BRET is achieved by the luminescent energy transfer from luciferase to the proximal fluorescent tracer that is bound to the target protein-luciferase fusion. The BRET assay specificity is governed by tight distance constraints. Test compounds that are applied to the cells and specifically engage the intracellular target protein-luciferase fusion displaces the tracer and results in a decrease in BRET.



3. Assay Components

Target

- Protein of interest with NanoLuc fusion
- Known ligand or inhibitor

Tracer

- Cell-permeable fluorescent tracer
- Available from Promega or can be custom made for novel targets

Substrate for NanoLuc

- Furimazine reacts with NanoLuc inside cell
- Emits blue light (450 nm), energy transfer to fluorescent dye (>600 nm)

Extracellular NanoLuc inhibitor

- Cellular debris is commonly observed in populations of rapidly-dividing live cells in culture
- Extracellular NanoLuc inhibitor ensures BRET measurements originate only from inside intact cells

January 2016



www.promega.com









First generation chronic myelogenous leukemia (CML) drug Imatinib shows shorter residence time at DDR1 kinase compared to second generation drugs approved or in development.